Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.

Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS.

Medicine (Baltimore). 2019 Nov;98(44):e17692. doi: 10.1097/MD.0000000000017692.

2.

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.

Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH.

Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398. doi: 10.1016/S2468-1253(19)30039-1. Epub 2019 Mar 20.

PMID:
30902670
3.

Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY.

JAMA Intern Med. 2019 May 1;179(5):633-640. doi: 10.1001/jamainternmed.2018.8342.

PMID:
30882847
4.

Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib.

Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS.

JGH Open. 2018 Oct 15;3(1):10-16. doi: 10.1002/jgh3.12096. eCollection 2019 Feb.

5.

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma.

Lee SW, Lee TY, Yang SS, Tong CF, Yeh HZ, Chang CS.

Gastroenterology Res. 2019 Feb;12(1):16-20. doi: 10.14740/gr1109. Epub 2019 Feb 26.

6.

Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].

Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY.

J Hepatol. 2019 Mar;70(3):581. doi: 10.1016/j.jhep.2018.12.010. Epub 2019 Jan 8. No abstract available.

PMID:
30635242
7.

The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.

Lee TY, Yang SS.

J Formos Med Assoc. 2018 Nov;117(11):1036-1037. doi: 10.1016/j.jfma.2018.09.013. Epub 2018 Oct 6. No abstract available.

8.

Possible Synergistic Effects of Glutathione and C-Reactive Protein in the Progression of Liver Cirrhosis.

Lai CY, Cheng SB, Lee TY, Liu HT, Huang SC, Huang YC.

Nutrients. 2018 May 27;10(6). pii: E678. doi: 10.3390/nu10060678.

9.

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals.

Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS.

Gastroenterology Res. 2018 Apr;11(2):124-129. doi: 10.14740/gr971w. Epub 2018 Apr 7.

10.

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.

Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY.

J Hepatol. 2018 Aug;69(2):278-285. doi: 10.1016/j.jhep.2018.02.032. Epub 2018 Mar 16. Erratum in: J Hepatol. 2019 Mar;70(3):581.

PMID:
29551708
11.

Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population.

Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS.

Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):45-48. doi: 10.1016/j.hbpd.2018.01.007. Epub 2018 Jan 31.

PMID:
29428103
12.

Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.

Hsu YC, Ho HJ, Lee TY, Huang YT, Wu MS, Lin JT, Wu CY, El-Serag HB.

J Viral Hepat. 2018 May;25(5):543-551. doi: 10.1111/jvh.12832. Epub 2018 Mar 30.

PMID:
29193536
13.

Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.

Huang YK, Yen CL, Shiu SI, Lee SW, Chang PY, Yeh HZ, Lee TY.

PLoS One. 2017 Nov 30;12(11):e0188999. doi: 10.1371/journal.pone.0188999. eCollection 2017.

14.

Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up.

Liao YJ, Li YC, Lee SW, Wu CY, Yang SS, Yeh HZ, Chang CS, Lee TY.

J Chin Med Assoc. 2017 Dec;80(12):758-765. doi: 10.1016/j.jcma.2017.07.009. Epub 2017 Sep 30.

15.

Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.

Lee TY, Hsu YC, Yu SH, Lin JT, Wu MS, Wu CY.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):947-954.e4. doi: 10.1016/j.cgh.2017.09.031. Epub 2017 Sep 22.

PMID:
28951229
16.
17.

The ultra-short virological dynamics in response to entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation.

Lee TY, Chen CY, Lia HC, Hsu YC, Yang SS.

Antivir Ther. 2018;23(1):77-85. doi: 10.3851/IMP3183.

PMID:
28671553
18.

Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.

Lee SW, Yang SS, Lee TY, Yeh HZ, Lu IT, Chang CS.

J Gastrointestin Liver Dis. 2017 Jun;26(2):205-206. doi: 10.15403/jgld.2014.1121.261.yeh. No abstract available.

PMID:
28617895
19.

The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.

Lee TY, Wu JC, Yu SH, Lin JT, Wu MS, Wu CY.

Int J Cancer. 2017 Oct 1;141(7):1307-1314. doi: 10.1002/ijc.30784. Epub 2017 Jun 30.

20.

The Diagnostic Value of Alarm Features for Identifying Types and Stages of Upper Gastrointestinal Malignancies.

Lee SW, Chang CS, Yeh HJ, Lien HC, Lee TY, Peng YC.

Gastroenterology Res. 2017 Apr;10(2):120-125. doi: 10.14740/gr826w. Epub 2017 Apr 19.

Supplemental Content

Loading ...
Support Center